Avanos Medical Acquires Nexus Medical to Strengthen Nutrition and Medication Delivery in Critical Care
MWN-AI** Summary
Avanos Medical, Inc. (NYSE: AVNS), a prominent medical technology company, has announced the acquisition of Nexus Medical, LLC, a Kansas-based medical device firm recognized for its innovative TKO® anti-reflux needleless connector technology. This acquisition, revealed on September 15, 2025, is designed to enhance Avanos’s Specialty Nutrition Systems business and bolster the delivery of nutrition and medication in critical care settings, particularly in Neonatal and Pediatric Intensive Care Units (NICUs and PICUs).
The TKO® technology features a patented, pressure-activated tri-seal silicone valve that significantly minimizes blood reflux, thereby reducing risks associated with catheter occlusions, delays in therapy, and potential infections during intravenous nutrition and medication delivery. According to Avanos CEO Dave Pacitti, this acquisition aligns seamlessly with the company's strategy to promote safer, innovative solutions throughout the critical care spectrum. By incorporating Nexus's offerings, Avanos aims to support clinicians in providing consistent care, ultimately improving patient outcomes.
Kerr Holbrook, Avanos's Chief Commercial Officer, highlighted that the TKO® connector complements Avanos's existing product lines and is expected to add immediate value in critical care environments, assisting clinicians in delivering treatment more reliably and efficiently. The acquisition has been financed through Avanos's available cash reserves and is anticipated to positively impact both revenue growth and earnings per share immediately.
This strategic move reflects Avanos Medical's ongoing commitment to addressing critical healthcare needs and enhancing patient safety through advanced clinical solutions. More information about Avanos and its product lines can be found on their official website and various social media platforms.
MWN-AI** Analysis
Avanos Medical's recent acquisition of Nexus Medical represents a strategic move to enhance its offerings in critical care, specifically in nutrition and medication delivery systems. This acquisition should be viewed positively by investors, as it not only adds valuable technology to Avanos' specialty nutrition division but also underscores the company's commitment to innovation, especially in high-acuity environments such as NICUs and PICUs where patient safety is paramount.
The Nexus TKO® technology, which minimizes blood reflux and reduces the risk of catheter occlusions and infections, strengthens Avanos’ product portfolio at a time when healthcare providers are increasingly focused on safety and efficacy in medication delivery. Since the acquisition is said to be immediately accretive to revenue growth and earnings per share, investors may expect an uptick in Avanos’ financial performance in the coming quarters.
Moreover, financing the acquisition with available cash reflects a disciplined approach to capital management, suggesting that the company maintains strong liquidity. This prudent capital allocation strategy can bolster investor confidence, especially given the competitive landscape of medical technology.
Going forward, investors should watch for Avanos' integration of Nexus technology and how it impacts sales and customer adoption rates. The company's ability to effectively market the combined strengths of their product lines could prove crucial for capturing greater market share in a growing sector.
In summary, Avanos Medical's acquisition of Nexus Medical offers a significant opportunity for growth. Investors might consider accumulating shares of AVNS as the company capitalizes on this strategic expansion, with the expectation that improvements in financial metrics will follow as the integration progresses.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
ALPHARETTA, Ga. , Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas .
Nexus is the maker of the proprietary TKO ® anti-reflux needleless connector technology, designed to support safer, more consistent nutrition and medication delivery in high-acuity settings, including Neonatal and Pediatric Intensive Care Units (NICUs and PICUs).
The acquisition adds complementary technology to Avanos' Specialty Nutrition Systems business and reinforces the company's focus on safe, reliable therapy delivery for the neonatal patient population.
"This acquisition is a clear extension of our strategy to deliver smarter, safer solutions across the critical care spectrum," said Dave Pacitti , Avanos chief executive officer. "We are proud to add the Nexus TKO ® technology and the full breadth of Nexus' offerings to our portfolio as we continue investing in meaningful innovation that helps clinicians provide consistent care and improve outcomes for patients who need it most."
The TKO ® needleless connector features a patented, pressure-activated tri-seal silicone valve that minimizes blood reflux – a known contributor to catheter occlusions, therapy delays, and infection risk during IV-based nutrition and medication delivery.*
"Nexus TKO ® fits naturally into our Specialty Nutrition Systems business and is expected to deliver immediate value in NICU and PICU care," said Kerr Holbrook , Avanos' chief commercial officer. "It's a practical, trusted solution that helps clinicians reduce disruptions and deliver therapy with greater consistency and ease."
Avanos financed the acquisition with available cash. The company expects the acquisition to be immediately accretive to both revenue growth and earnings per share.
About Avanos Medical
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple product categories. For more information, visit www.avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.
About Nexus Medical
Founded in 2001, Nexus Medical invented the anti-reflux category in needleless connectors to solve the unintended consequences of blood reflux in IV catheters, including intraluminal thrombotic occlusions, catheter failure, and infections. As the most studied needleless connector on the market, the Nexus TKO ® anti-reflux technology is an evidence-based way to simplify the complexity of IV therapy and improve patient safety. For more information, call (913) 451-2234 or visit www.nexusmedical.com .
*CLAIM ON FILE
SOURCE Avanos Medical
FAQ**
How does the acquisition of Nexus Medical LLC enhance Avanos Medical Inc. (AVNS) product offerings in the critical care sector, particularly for NICUs and PICUs?
What specific financial metrics does Avanos Medical Inc. (AVNS) anticipate will improve as a result of the acquisition of Nexus Medical, and how will this affect shareholder value?
In what ways does the patented TKO ® anti-reflux technology from Nexus Medical align with Avanos Medical Inc. (AVNS) vision for safe and reliable therapy delivery?
Can Avanos Medical Inc. (AVNS) provide insights on the anticipated timeline for realizing the expected immediate value from the Nexus Medical acquisition in terms of revenue growth?
**MWN-AI FAQ is based on asking OpenAI questions about Avanos Medical Inc. (NYSE: AVNS).
NASDAQ: AVNS
AVNS Trading
3.63% G/L:
$13.86 Last:
124,280 Volume:
$13.67 Open:
